| pubmed-article:21095265 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0014653 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0020507 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0560187 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0038257 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0070166 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0441800 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0522523 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0919553 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:21095265 | lifeskim:mentions | umls-concept:C0388929 | lld:lifeskim |
| pubmed-article:21095265 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21095265 | pubmed:dateCreated | 2010-11-24 | lld:pubmed |
| pubmed-article:21095265 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095265 | pubmed:abstractText | The optimal duration of clopidogrel therapy after coronary stenting is debated because of the scarcity of randomized controlled trials and inconsistencies arising from registry data. Although prolonged clopidogrel therapy after bare metal stenting is regarded as an effective secondary prevention measure, the safety profile of drug-eluting stents itself has been questioned in patients not receiving ? 12 months of dual-antiplatelet therapy. | lld:pubmed |
| pubmed-article:21095265 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21095265 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095265 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21095265 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095265 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095265 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095265 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21095265 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:21095265 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ColomboFederi... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:FerrariFabriz... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:FerrariRobert... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ParrinelloGio... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ValgimigliMar... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:TseW LWL | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:MarchesiniJle... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:PercocoGianfr... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:CampoGianluca... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:BorghesiMarco... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ArcozziChiara... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:FrangioneAlic... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:TebaldiMatteo... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ScaloneAntone... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:TumscitzCarlo... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:KubbajehMoh'd... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:ZuffiAndreaA | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:CangianoElisa... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:CavazzaCateri... | lld:pubmed |
| pubmed-article:21095265 | pubmed:author | pubmed-author:MinarelliMoni... | lld:pubmed |
| pubmed-article:21095265 | pubmed:copyrightInfo | Copyright © 2010 Mosby, Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21095265 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21095265 | pubmed:volume | 160 | lld:pubmed |
| pubmed-article:21095265 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21095265 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21095265 | pubmed:pagination | 804-11 | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:meshHeading | pubmed-meshheading:21095265... | lld:pubmed |
| pubmed-article:21095265 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21095265 | pubmed:articleTitle | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). | lld:pubmed |
| pubmed-article:21095265 | pubmed:affiliation | Cardiology Department, University of Ferrara, Ferrara, Italy. vlgmrc@unife.it | lld:pubmed |
| pubmed-article:21095265 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21095265 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21095265 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21095265 | pubmed:publicationType | Multicenter Study | lld:pubmed |
